Fig. 5: Analysis of EV carrying cancer-specific KRAS mutated proteins.
From: Multiplexed analysis of EV reveals specific biomarker composition with diagnostic impact
EV carrying cancer-specific mutated proteins (KRASG12D (PANC-1, ASPC1, LS180); KRASG12V (CAPAN-2); and KRASG12S (A549) were analyzed for co-expression of tetraspanins commonly used for affinity purification of EV (error bar: mean ± standard deviation). Number of EV analyzed: LS180: 5500; ASPC1: 6400; PANC-1: 3600; A549: 8200; CAPAN-2: 4800. A Profiling of EV for different KRASmut proteins in EV. Note that 15–45% of all EV exhibit KRASmut protein in their EV. This number decreases considerably when accounting for concurrent tetraspanin positivity. B The data show considerable loss (50–80%) of KRASmut-positive EV with affinity purification.
